|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
p2596119 |
| 005 |
20240206154732.0 |
| 006 |
m o d |
| 007 |
cr bn |||||||| |
| 008 |
190502s2018 onc o 000 0 eng |
| 035 |
|
|
|a (DNLM)BKSHLF:NBK540040
|
| 035 |
|
|
|a 1747350
|
| 040 |
|
|
|a DNLM
|b eng
|e rda
|c DNLM
|d UtOrBLW
|
| 042 |
|
|
|a pcc
|
| 043 |
|
|
|a n-cn---
|
| 060 |
0 |
0 |
|a WE 550
|
| 110 |
2 |
|
|a CADTH Canadian Drug Expert Committee,
|e author.
|0 n 2019180882
|
| 240 |
1 |
0 |
|a CADTH Canadian Drug Expert Committee recommendation. AbobotulinumtoxinA (Dysport therapeutic--Ipsen Biopharmaceuticals Canada, Inc.) (August 2018)
|
| 245 |
1 |
0 |
|a CADTH Canadian Drug Expert Committee recommendation.
|p AbobotulinumtoxinA (Dysport therapeutic--Ipsen Biopharmaceuticals Canada, Inc.) :
|b indication : for the symptomatic treatment of lower limb spasticity (LLS) in pediatric patients two years of age and older.
|
| 246 |
1 |
|
|a AbobotulinumtoxinA (Dysport therapeutic--Ipsen Biopharmaceuticals Canada, Inc.)
|
| 246 |
1 |
|
|a Drug reimbursement recommendation AbobotulinumtoxinA (Dysport Therapeutic)
|
| 250 |
|
|
|a Version: Final.
|
| 264 |
|
1 |
|a Ottawa (ON) :
|b Canadian Agency for Drugs and Technologies in Health,
|c August 2018.
|
| 300 |
|
|
|a 1 online resource (1 PDF file (8 pages)).
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a CADTH common drug review
|
| 536 |
|
|
|a Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.
|
| 588 |
|
|
|a Description based on online resource; title from PDF title page (viewed June 8, 2019).
|
| 650 |
1 |
2 |
|a Muscle Spasticity
|x drug therapy.
|0 D009128Q000188
|
| 650 |
1 |
2 |
|a Child.
|0 D002648
|
| 650 |
2 |
2 |
|a Lower Extremity.
|0 D035002
|
| 650 |
2 |
2 |
|a Botulinum Toxins, Type A
|x therapeutic use.
|0 D019274Q000627
|
| 650 |
2 |
2 |
|a Cost-Benefit Analysis.
|0 D003362
|
| 650 |
2 |
2 |
|a Insurance, Health, Reimbursement.
|0 D007349
|
| 650 |
|
7 |
|a Children.
|2 homoit
|0 homoit0000255
|
| 650 |
|
7 |
|a Family members.
|2 homoit
|0 homoit0000421
|
| 651 |
|
2 |
|a Canada.
|0 D002170
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health,
|e issuing body.
|0 n 2007182676
|
| 830 |
|
0 |
|a Common drug review clinical review report.
|0 n 2014186107
|
| 951 |
|
|
|a 2596119
|
| 998 |
|
|
|a BKSHLF
|b 20190502
|
| 999 |
f |
f |
|i f4e3cf8e-0a16-510f-b41d-517bb8f4f406
|s dc7b415e-639c-555a-b4aa-be5f048a806d
|t 0
|
| 952 |
f |
f |
|a Massachusetts College of Pharmacy and Health Sciences
|b Online
|c Online
|d E-Collections
|t 0
|e NCBI
|h Other scheme
|
| 856 |
4 |
0 |
|t 0
|u http://www.ncbi.nlm.nih.gov/books/NBK540040/
|y Full text
|
